- The disease
- Hypoxic ischaemic encephalopathy (HIE) is a form of brain injury that occurs when the brain is deprived of adequate oxygen and blood flow. It is most commonly associated with birth asphyxia in newborns, where it remains a leading cause of neonatal death and long-term neurodevelopmental disability. Current standard of care for neonatal HIE is therapeutic hypothermia (whole-body or head cooling), which is initiated within six hours of birth. There are no approved pharmacological agents specifically indicated for HIE.
- What the asset is trying to do
- ARG-007, also referred to as Xaranetide, is a peptide therapeutic being developed by Argenica Therapeutics. The precise molecular target of ARG-007 is not disclosed in the available input data. As a peptide therapeutic, it belongs to a class of compounds derived from or mimicking naturally occurring peptide sequences, which are generally designed to interact with specific biological pathways involved in cell survival or injury response. The company has also studied ARG-007 in acute ischaemic stroke (a related condition involving disrupted blood flow to the brain), with a completed Phase 2 trial registered under ACTRN12621000385922.
- What the trial is measuring, and why it matters
- No clinical trial has been registered or disclosed for ARG-007 in the HIE indication at this time, and the asset is described as preclinical in this setting. Typical primary endpoints in neonatal HIE trials include measures of brain injury severity (assessed by magnetic resonance imaging), mortality, and neurodevelopmental outcomes at defined follow-up ages. The company has established a Clinical Advisory Committee to advance a Phase 2b programme (per ASX announcement, 13 May 2026) and is progressing an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA), having completed all three FDA-requested assays (per ASX announcement, 10 June 2026).
- Efficacy benchmarks in this setting
- In neonatal HIE, therapeutic hypothermia is the established standard of care. Clinical trials of hypothermia, including the TOBY trial (Azzopardi et al, New England Journal of Medicine, 2008), reported that cooling reduced the combined outcome of death or major neurodevelopmental disability compared with normothermia in term infants. Specific outcome rates from those trials are cited in the published literature. No pharmacological add-on therapy has demonstrated sufficient efficacy to achieve regulatory approval in this indication. ARG-007 is at preclinical stage in HIE, and no clinical efficacy data for this asset in this indication are available for comparison with established benchmarks.